Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients

Description

Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.

Conditions

Venous Thromboembolism

Talk to us

Study Overview

On this page

Study Details

Study overview

Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.

Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients

Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients

Condition
Venous Thromboembolism
Intervention / Treatment

-

Contacts and Locations

Richardson

Methodist Richardson Medical Center, Richardson, Texas, United States, 75082

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Enoxaparin dose (appropriate for kidney function)
  • * Charlson comorbidity index (CCI) score
  • * Padua prediction score for risk of VTE
  • * IMPROVE \[International Medical Prevention Registry on VTE\] bleeding risk assessment score
  • * ICU status
  • * Number of thromboembolic events
  • * Length of stay
  • * Readmissions for DVT and/or PE
  • * In-hospital mortality with associated DVT or PE
  • * Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:
  • * Bleeding events
  • * Type of bleeding event

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Methodist Health System,

Betina Daniel, PharmD, PRINCIPAL_INVESTIGATOR, Methodist

Study Record Dates

2024-11-17